Pharma BD Deal Intelligence
A slow-burn bet still in progress: Merck paid $2.7B for ArQule's BTK inhibitor ARQ 531 (now nemtabrutinib), which six years later sits in pivotal Phase 3 BELLWAVE trials for chronic lymphocytic leukemia/small lymphocytic lymphoma—including a head-to-head against ibrutinib—but has yet to deliver a pivotal efficacy readout or approval.
Merck acquired ArQule for $2.7B for BTK inhibitor ARQ 531.
Merck to acquire ArQule for $20 per share approximately $2.7 billion advancing leadership in oncology with novel BTK inhibitor ARQ 531.
Merck completes acquisition of ArQule on January 16 2020 gaining clinical-stage oral kinase inhibitors for B-cell malignancies treatment.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck acquired ArQule for $2.7B (closed January 2020) for its lead asset ARQ 531, a reversible, non-covalent BTK inhibitor now developed as nemtabrutinib (MK-1026). As of late 2025 the asset has advanced into multiple registrational Phase 3 BELLWAVE trials in CLL/SLL (incl. a head-to-head BELLWAVE-011 vs ibrutinib/acalabrutinib), though it remains pre-approval with no pivotal efficacy readout.
Nemtabrutinib (MK-1026) is a Phase 3 non-covalent BTK/SFK inhibitor; it enters a saturated B-cell malignancy landscape with four established MOA classes. Covalent BTK inhibitors: Imbruvica (ibrutinib, J&J/AbbVie) generated roughly $9B global at peak and now declining; Calquence (acalabrutinib, AstraZeneca) at roughly $2.5B and growing in CLL/MCL; Brukinsa (zanubrutinib, BeiGene) FDA-approved in CLL, WM, MZL, MCL, FL showing superiority to ibrutinib in ALPINE Phase 3 (NEJM 2023). Non-covalent (reversible) BTK inhibitors: Jaypirca (pirtobrutinib, Lilly) is approved in post-cBTKi MCL (2023) and CLL (2023), with head-to-head BRUIN CLL-321 data versus investigator choice; nemtabrutinib competes in this same C481S-mutant post-cBTKi niche. BCL-2 inhibitors: Venclexta (venetoclax, AbbVie/Roche) anchors CLL frontline and is a standard combo partner. CD20 mAbs/bispecifics/CAR-T: Gazyva (obinutuzumab) and Rituxan (rituximab) biosimilars are backbone; Columvi, Epkinly, and CD19 CAR-Ts (Yescarta, Breyanzi, Kymriah) pressure late-line. Commercial threat for nemtabrutinib is Jaypirca's first-mover advantage in post-covalent-BTK space plus aggressive frontline erosion by venetoclax-based chemo-free regimens; Merck needs differentiation on off-target kinase breadth or depth of response in BTK-double-refractory disease.
Nemtabrutinib (MK-1026) positions as a non-covalent BTK inhibitor in CLL; it competes across four MOA classes in a franchise dominated by chronic dosing and emerging fixed-duration regimens. Covalent BTK inhibitors: Calquence (acalabrutinib, AstraZeneca) leads frontline and R/R CLL with ELEVATE-TN and ELEVATE-RR evidence (roughly $2.5B global 2023); Brukinsa (zanubrutinib, BeiGene) demonstrated superior PFS versus ibrutinib in ALPINE Phase 3 and is the fastest-growing BTKi globally; Imbruvica (ibrutinib, J&J/AbbVie) is in secular decline post-RESONATE-2 era. Non-covalent BTK inhibitors: Jaypirca (pirtobrutinib, Lilly) is FDA-approved in R/R CLL after BTK/BCL-2 inhibitor failure (BRUIN-CLL, NEJM 2023), the direct class comparator for nemtabrutinib. BCL-2 inhibitors: Venclexta (venetoclax, AbbVie/Roche) with obinutuzumab established fixed-duration 1L CLL (CLL14) and with ibrutinib (GLOW). PI3K inhibitors: Copiktra (duvelisib, Secura Bio) and Zydelig (idelalisib, Gilead) are niche after safety-driven withdrawals. CD19 CAR-T: Breyanzi (lisocabtagene maraleucel, BMS) was approved in R/R CLL in 2024 (TRANSCEND-CLL 004) for triple-class exposed. Commercial threat for nemtabrutinib is pirtobrutinib's first-to-market non-covalent position in post-cBTKi patients plus fixed-duration venetoclax regimens shrinking chronic BTKi duration.
Merck completed $2.7B acquisition of ArQule, gaining ARQ 531, a next-generation reversible BTK inhibitor for B-cell malignancies.
Merck advanced MK-1026 (formerly ARQ 531) through Phase 2 in CLL and B-cell cancers, competing in intensifying BTK landscape.
ArQule's ARQ 531 — now nemtabrutinib (MK-1026), a reversible non-covalent BTK inhibitor — has progressed into multiple registrational Phase 3 trials in CLL/SLL (BELLWAVE-008 vs chemoimmunotherapy in untreated TP53-WT; BELLWAVE-010 + venetoclax in R/R; BELLWAVE-011 head-to-head vs ibrutinib/acalabrutinib in untreated). No pivotal efficacy readout or FDA approval yet.
MK-1026 in mid-stage development, no pivotal data. $2.7B was premium for Phase 1 asset. Competitive BTK landscape intensified with multiple next-gen inhibitors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / ArQule Inc. (this deal) | 2019 | $2.7B | 58 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2019 deals · Merck & Co. Inc. deals · Oncology deals